Source-grounded facts extracted from Organon & Co.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Organon & Co. shareholders approved To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.
“4. To ratify the appointment by the Company's Audit Committee of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm”
Organon & Co. shareholders approved To approve an amendment and restatement of the Organon & Co. 2021 Incentive Stock Plan at the 2026-06-09 meeting.
“3. To approve an amendment and restatement of the Organon & Co. 2021 Incentive Stock Plan”
Organon & Co. shareholders approved To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers at the 2026-06-09 meeting.
“2. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers”
Organon & Co. shareholders approved Election of ten directors nominated by the Board at the 2026-06-09 meeting.
“On June 9, 2026, the Company held its 2026 Annual Meeting, at which the Company's stockholders considered four proposals”
Organon & Co. reported quarter ended March 31, 2026 results: revenue $1.460 billion, net income $146 million, EPS $0.55.
“Organon Reports Results for the First Quarter Ended March 31, 2026 · First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. · First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71. · First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%.”
Organon & Co. entered into Agreement and Plan of Merger with Sun Pharmaceutical Holdings USA, Inc., Sun Pharma America, Inc., Sun Pharmaceutical Industries Limited, Sun Pharma Canada Inc., Sun Pharma (Netherlands) B.V. (effective 2026-04-26).
“On April 26, 2026, Organon & Co. (the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Sun Pharmaceutical Holdings USA, Inc., a Delaware corporation (“ Parent ”), Sun Pharma America, Inc., a Delaware corporation and wholly owned subsidiary of Parent and/or its affiliates (“ Merger Sub ”) and, solely for the purposes of certain covered provisions of the Merger Agreement, Sun Pharmaceutical Industries Limited, an entity organized under the laws of India (“ India Parent ”), Sun Pharma Canada Inc., a corporation incorporated under the laws of the Province of Ontario and Sun Pharma (Netherlands) B.V., a private company with limited liability incorporated under the laws of the Netherlands, pursuant to which, among other things, Merger Sub will merge with and into the Company (the “ Merger ”), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent.”
Ramona A. Sequeira was appointed as Director at Organon & Co..
“the appointment of Ramona A. Sequeira will become immediately effective to fill the resulting vacancy.”
Susanne Fiedler departed as Chief Commercial Officer at Organon & Co..
“On January 15, 2025, Organon & Co. (the “ Company ”) announced that effective January 15, 2025, Susanne Fiedler ceased performing her functions as Chief Commercial Officer.”
Organon & Co. entered into Amendment No. 2 to Senior Secured Credit Agreement and Amendment to Security Agreement with JPMorgan Chase Bank, N.A., as administrative agent and collateral agent valued at amendment to existing senior secured credit facilities: extended maturity of Dollar Term Facility to (effective 2024-05-17).
“On May 17, 2024, the Companies entered into Amendment No. 2 to Senior Secured Credit Agreement and Amendment to Security Agreement (the “ Credit Agreement Amendment ”), by and among the Companies as borrowers, the Subsidiary Guarantors, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent.”
Organon & Co. entered into Indentures for 6.750% Senior Secured Notes due 2034 and 7.875% Senior Unsecured Notes due 2034 with U.S. Bank Trust Company, National Association valued at two series of notes totaling $1,000,000,000 principal amount: $500,000,000 6.750% senior secured not (effective 2024-05-17).
“On May 17, 2024, Organon & Co. (the “ Company ”) and Organon Foreign Debt Co-Issuer B.V., a Dutch private limited liability company ( besloten vennootschap met beperkte aansprakelijkheid ) and wholly-owned subsidiary of Organon (the “ Co-Issuer ”, and together with the Company, the “ Companies ”), closed their previously announced private offering (the “ Notes Offering ”) of $500 million of 6.750% senior secured notes due 2034 (the “ Secured Notes ”) and $500 million of 7.875% senior unsecured notes due 2034 (the “ Unsecured Notes ” and, together with the Secured Notes, the “ Notes ”).”
Organon & Co. reported the first quarter ended March 31, 2024 results: revenue $1,622 million, net income $201 million, EPS $0.78. Guidance reaffirmed.
“First quarter 2024 revenue of $1,622 million, up 5% on an as-reported basis and 7% at constant currency • First quarter 2024 diluted earnings per share of $0.78 and non-GAAP Adjusted diluted earnings per share of $1.22; both reported and non-GAAP Adjusted diluted earnings per share include $15 million expense, or $(0.05) per share, for acquired in-process research and development (IPR&D) and milestones • First quarter 2024 net income of $201 million and Adjusted EBITDA (non-GAAP) of $538 million • Full year 2024 financial guidance ranges affirmed”
Organon & Co. updated its the quarter and full year ended December 31, 2023 guidance (reaffirmed).
“On February 15, 2024, Organon & Co. (the “ Company ”) issued a press release (the “ Earnings Release ”) regarding its results for the quarter and full year ended December 31, 2023.”
Dr. Sandra Milligan departed as Head of Research and Development at Organon & Co..
“On December 5, 2023, Organon & Co. (the “ Company ”) announced that Dr. Sandra Milligan will be departing from the Company on January 5, 2024.”
Organon & Co. reported third quarter ended September 30, 2023 results: revenue $1,519 million, net income $58 million, EPS $0.23. Guidance lowered.
“Organon Reports Results for the Third Quarter Ended September 30, 2023 • Third quarter 2023 revenue of $1,519 million • Third quarter 2023 diluted earnings per share of $0.23”
Organon & Co. reported the second quarter ended June 30, 2023 results: revenue $1,608 million, net income $242 million, EPS $0.95. Guidance reaffirmed.
“Organon Reports Results for the Second Quarter Ended June 30, 2023 • Second quarter 2023 revenue of $1,608 million • Second quarter 2023 diluted earnings per share of $0.95”
Organon & Co. amended Amendment No. 1 with JPMorgan Chase Bank, N.A. (effective 2023-06-30).
“On June 30, 2023, Organon & Co. (the “ Company ”), as Lead Borrower, Organon Foreign Debt Co-Issuer B.V., as Co-Borrower, and certain subsidiaries of the Company as Loan Parties (the foregoing being collectively referred to herein as “ Organon ”) entered into Amendment No. 1 (“ Amendment No. 1 ”) to the Senior Secured Credit Agreement, dated as of June 2, 2021, by and among Organon and JPMorgan Chase Bank, N.A., as Administrative Agent and Collateral Agent (the “ Credit Agreement ” and as amended by Amendment No. 1, the “ Amended Agreement ”).”
Organon & Co. shareholders approved To ratify the appointment by the Company’s Audit Committee of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm at the 2023-06-06 meeting.
“For Against Abstain Broker Non- Votes 1 215,254,031 840,020 454,264 0”
Organon & Co. shareholders approved To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers at the 2023-06-06 meeting.
“For Against Abstain Broker Non-Votes 1 170,522,652 11,916,370 815,895 32,293,398”
Organon & Co. shareholders approved To elect the four Class II directors nominated by the Company’s Board of Directors to serve until the 2025 annual meeting at the 2023-06-06 meeting.
“Nominee For Withhold Abstain Broker Non- Votes 1 Carrie S. Cox 161,582,913 21,364,441 307,563 33,293,398 Alan Ezekowitz, M.D. 181,298,050 1,681,234 275,633 33,293,398 Helene Gayle, M.D. 180,024,350 2,950,230 280,337 33,293,398 Deborah Leone 181,439,869 1,544,341 270,707 33,293,398”
Organon & Co. reported the fourth quarter and full year ended December 31, 2022 results: revenue $1,485 million, net income $108 million, EPS $0.42 per diluted share.
“For the fourth quarter of 2022, total revenue was $1,485 million, a decrease of 7% as-reported and an increase of 1% excluding the impact of foreign currency (ex-FX), compared with the fourth quarter of 2021.”
Organon & Co.: Amendment and restatement of bylaws primarily to comply with universal proxy card rules, with technical, modernizing, and clarifying changes (effective 2022-12-06).
“On December 6, 2022, the Board of Directors Organon & Co. (the “ Company ”) approved and adopted Amended and Restated Bylaws (as so amended and restated, the “ Amended Bylaws ”), effective December 6, 2022. The Amended Bylaws amended and restated the Company’s prior bylaws primarily to make compliance with the applicable provisions of the “universal proxy card” rules”
Organon & Co. reported the third quarter ended September 30, 2022 results: revenue $1,537 million, net income 227, EPS $0.89.
“Halchak (614) 314-8094 Kate Vossen (732) 675-8448 (201) 275-2711 Organon rep orts results for the third quarter ended September 30, 2022 · Third quarter 2022 revenues of $1,537 million · Third quarter diluted earnings per share from continuing operations of $0.89 and non-GAAP adjusted diluted earnings per share from continuing operations of $1.32 · Both”
Deborah H. Telman resigned as Executive Vice President, General Counsel and Corporate Secretary at Organon & Co..
“On July 7, 2022, Deborah H. Telman gave notice of her decision to resign from her position as Executive Vice President, General Counsel and Corporate Secretary of Organon & Co., effective July 22, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.